drugset
drugset / Trial / NCT00705874

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

NCT00705874 ↗

Phase 1 Completed 172 enrolled Progen Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will aims to determine the maximum tolerated dose of CGC-11047 when used in individual combinations with gemcitabine, or docetaxel, or bevacizumab, or erlotinib or cisplatin or 5-flurouracil or sunitinib in one of 7 treatment arms. The dose of CGC-11047 will be escalated until the maximum tolerated dose is established.

Timeline

Start
2006-05
Primary completion
2011-08
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject CGC-11047 Unknown 50 mg Intravenous
Background 5-flurouracil Unknown 500 mg/m2 Intravenous
Background Bevacizumab Monoclonal antibody 5 mg/kg Intravenous
Background Cisplatin Other / unclassified 80 mg/m2 Intravenous
Background Docetaxel Small molecule 75 mg/m2 Intravenous
Background Erlotinib Small molecule 150 mg Oral
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous
Background Leucovorin Small molecule 500 mg/m2 Intravenous
Background Sunitinib Small molecule 50 mg Oral

Indications

cancer